Metz C A, Freedman R S, Magrina J F
Gynecol Oncol. 1987 May;27(1):84-9. doi: 10.1016/0090-8258(87)90233-2.
In a double-blind, placebo-controlled trial, the antiemetic efficacy of a total of 1-2 g methylprednisolone sodium succinate (MPSS) alone versus placebo was evaluated over the first three courses of chemotherapy in a group of 27 women receiving moderate to high-dose cis-platinum (50-118 mg/m2) for ovarian or cervical carcinomas. Antiemetic protection was classified as total (no emesis), major (one or two bouts), minor (three to five bouts), or minimal (six or more bouts). Total or major protection occurred in 10/26 (38.5%) of the MPSS cycles and in 6/24 (25%) of the placebo cycles (NS). A significant number of placebo patients (7/14 placebo versus 1/13 MPSS, P = 0.02) dropped out of the study due to lack of efficacy. Patient evaluations completed 24 hr before and after each course of chemotherapy indicated no treatment effect on pain, appetite, nausea, drowsiness, anxiety, sense of well-being, or sleep. Physician and patient global evaluations of antiemetic efficacy favored treatment with MPSS. Evidence of the efficacy of single-drug MPSS antiemetic therapy during non-cis-platinum or low-dose cis-platinum (less than 50 mg/m2) chemotherapy can be found in the literature. The results of this study, however, do not support the use of MPSS alone with high-dose cis-platinum chemotherapy.
在一项双盲、安慰剂对照试验中，对27名接受中高剂量顺铂（50 - 118 mg/m²）治疗卵巢癌或宫颈癌的女性患者，在前三个化疗疗程中评估了单独使用总量为1 - 2 g琥珀酸钠甲泼尼龙（MPSS）与安慰剂相比的止吐效果。止吐保护分为完全（无呕吐）、主要（一或两次发作）、轻微（三至五次发作）或最小（六次或更多次发作）。完全或主要保护在MPSS治疗周期的10/26（38.5%）中出现，在安慰剂治疗周期的6/24（25%）中出现（无显著性差异）。相当数量的安慰剂患者（7/14安慰剂组对比1/13 MPSS组，P = 0.02）因疗效不佳退出研究。每个化疗疗程前后24小时完成的患者评估表明，治疗对疼痛、食欲、恶心、嗜睡、焦虑、幸福感或睡眠无影响。医生和患者对止吐效果的整体评估倾向于MPSS治疗。在文献中可找到单药MPSS止吐疗法在非顺铂或低剂量顺铂（小于50 mg/m²）化疗期间有效的证据。然而，本研究结果不支持在高剂量顺铂化疗中单独使用MPSS。
